Flossmoor, IL

Healthcare Research Network

Peripheral Nervous System Diseases

Osteoarthritis

Diabetic Neuropathies

Knee Osteoarthritis

Pain

Waldenstrom Macroglobulinemia

Mantle-Cell Lymphoma

Lymphoma

B-Cell Chronic Lymphocytic Leukemia

Pneumococcal Infections

X0002

BGB-3111

CNTX-4975-05

Zanubrutinib

NRD135SE.1

Tyrosine

James P. Rathmell, MD

BeiGene

Centrexion Therapeutics

Merck Sharp & Dohme (MSD)

Techfields

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the recurrence and the change in severity of adverse events.

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Healthcare Research Network | Flossmoor, IL

Site insights

Work at this site?

Active trials

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Trial sponsors